Pomalidomide-C6-CO2H is a high-purity E3 ligase ligand-linker conjugate specifically designed for use in PROTAC (Proteolysis Targeting Chimera) drug development. This compound features pomalidomide, a well-characterized E3 ligase ligand targeting cereblon (CRBN), connected through a six-carbon alkyl linker to a terminal carboxylic acid (CO2H) group. The carboxylic acid functionality enables efficient conjugation to target protein ligands, making it an optimal building block for constructing versatile PROTAC molecules.
* For research and manufacturing use only. Not for human or clinical use.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
Background Introduction
Pomalidomide-C6-CO2H is a specialized E3 ligase ligand-linker conjugate widely utilized in the development of PROTACs (Proteolysis Targeting Chimeras). By combining pomalidomide, a cereblon (CRBN) ligand, with a functionalized C6 alkyl linker terminated with a carboxylic acid (CO2H) group, this molecule serves as a powerful intermediate in targeted protein degradation research.
Mechanism
Pomalidomide-C6-CO2H operates by harnessing the body's ubiquitin-proteasome system (UPS) for selective protein degradation. In PROTAC construction, the pomalidomide moiety binds to the CRBN E3 ubiquitin ligase, while the reactive carboxylic acid permits further conjugation to other ligands, such as target protein binders. Upon successful linking, the resulting PROTAC molecule brings the E3 ligase and the target protein into close proximity, facilitating ubiquitination of the target and subsequent proteasomal degradation.
Applications
Pomalidomide-C6-CO2H is primarily used as a chemical building block in the design and synthesis of PROTACs and molecular glues to explore targeted protein degradation. Its applications include discovery research for novel therapeutics, functional genomics studies, target validation, and the development of next-generation protein degraders aimed at treating cancers, neurodegenerative diseases, and immunological disorders. The compound’s carboxyl-terminated linker allows flexible conjugation chemistry, making it ideal for constructing diverse proteolytic targeting molecules and for customizing linker lengths to optimize activity and selectivity in probe or drug development.
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
Please contact us with any specific requirements and we will get back to you as soon as possible.